"name","description","label","instanceType","uuid:ID","text","id"
"OBJ1","Main objective","","Objective","824ea3df-983d-459d-ac0f-98605bf24277","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","Objective_1"
"OBJ2","Safety","","Objective","7101446a-2fc9-40fc-aec7-ed27675f42a7","To document the safety profile of the xanomeline TTS.","Objective_2"
"OBJ3","Behaviour","","Objective","82585156-dad8-4b88-b28d-085f1b0d9d25","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","Objective_3"
"OBJ4","","","Objective","0a049cce-0870-4018-bc40-e0ad0cc21387","To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).","Objective_4"
"OBJ5","","","Objective","a20bf509-164c-431d-8f86-cbea47859c3e","To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).","Objective_5"
"OBJ6","","","Objective","daead3d2-2432-4cf2-96e1-d835b917c0aa","To assess the treatment response as a function of Apo E genotype.","Objective_6"
